 | • レポートコード：MRC2-11QY04964 • 出版社/出版日：QYResearch / 2020年11月20日 ※2024年版があります。お問い合わせください。 • レポート形態：英文、PDF、95ページ • 納品方法：Eメール（納期：2~3日） • 産業分類：ヘルスケア |
| Single User | ￥577,200 (USD3,900) | ▷ お問い合わせ |
| Multi User | ￥865,800 (USD5,850) | ▷ お問い合わせ |
| Enterprise License | ￥1,154,400 (USD7,800) | ▷ お問い合わせ |
• お支払方法：銀行振込（納品後、ご請求書送付）
レポート概要
| 当調査資料は子宮内膜ポリープ治療薬のグローバル市場について調査・分析したレポートです。種類別（経口、注射、その他）市場規模、用途別（病院、診療所、在宅医療、その他）市場規模、地域別（北米、米国、カナダ、ヨーロッパ、ドイツ、フランス、イギリス、イタリア、ロシア、アジア、日本、中国、韓国、インド、オーストラリア、台湾、中南米、メキシコ、ブラジル、アルゼンチン、中東・アフリカ、トルコ、サウジアラビア、UAE等）市場規模データ、主な企業情報と企業別市場シェア等が収録されています。 ・調査範囲 ・エグゼクティブサマリー ・企業別子宮内膜ポリープ治療薬の競争状況、市場シェア ・世界の子宮内膜ポリープ治療薬市場：種類別市場規模 2015年-2020年（経口、注射、その他） ・世界の子宮内膜ポリープ治療薬市場：種類別市場規模予測 2021年-2026年（経口、注射、その他） ・世界の子宮内膜ポリープ治療薬市場：用途別市場規模 2015年-2020年（病院、診療所、在宅医療、その他） ・世界の子宮内膜ポリープ治療薬市場：用途別市場規模予測 2021年-2026年（病院、診療所、在宅医療、その他） ・北米の子宮内膜ポリープ治療薬市場分析：米国、カナダ ・ヨーロッパの子宮内膜ポリープ治療薬市場分析：ドイツ、フランス、イギリス、イタリア、ロシア等 ・アジアの子宮内膜ポリープ治療薬市場分析：日本、中国、韓国、インド、オーストラリア、台湾等 ・中南米の子宮内膜ポリープ治療薬市場分析：メキシコ、ブラジル、アルゼンチン等 ・中東・アフリカの子宮内膜ポリープ治療薬市場分析：トルコ、サウジアラビア、UAE等 ・企業情報（企業概要、製品概要、販売量、企業動向） - 掲載企業（変更可能性あり）：GSK、Roche、Pfizer、Novartis、Merck、Bristol-Myers、Sanofi、Teva Pharmaceutical Industries、Amgen、Mylan、Sun Pharmaceutical Industries ・地域別市場規模予測（2021年-2026年）：北米市場、ヨーロッパ市場、アジア市場、中南米市場、中東・アフリカ市場 ・市場機会、課題、リスク、環境分析 ・バリューチェーン、販売チャネル分析 ・調査の結論 |
Uterine polyps are common gynecological diseases. Broadly speaking, it refers to all tumors attached to the uterine wall by slender pedicle. Mostly benign.
Market Analysis and Insights: Global Uterine Polyps Drug Market
The global Uterine Polyps Drug market size is projected to reach US$ XX million by 2026, from US$ XX million in 2020, at a CAGR of XX% during 2021-2026.
With industry-standard accuracy in analysis and high data integrity, the report makes a brilliant attempt to unveil key opportunities available in the global Uterine Polyps Drug market to help players in achieving a strong market position. Buyers of the report can access verified and reliable market forecasts, including those for the overall size of the global Uterine Polyps Drug market in terms of revenue.
On the whole, the report proves to be an effective tool that players can use to gain a competitive edge over their competitors and ensure lasting success in the global Uterine Polyps Drug market. All of the findings, data, and information provided in the report are validated and revalidated with the help of trustworthy sources. The analysts who have authored the report took a unique and industry-best research and analysis approach for an in-depth study of the global Uterine Polyps Drug market.
Global Uterine Polyps Drug Scope and Market Size
Uterine Polyps Drug market is segmented by Type, and by Application. Players, stakeholders, and other participants in the global Uterine Polyps Drug market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on revenue and forecast by Type and by Application in terms of revenue and forecast for the period 2015-2026.
Market segment by Type, the product can be split into
Oral
Injection
Other
Market segment by Application, split into
Hospital
Clinic
Homecare
Other
Based on regional and country-level analysis, the Uterine Polyps Drug market has been segmented as follows:
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Russia
Nordic
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia-Pacific
Latin America
Mexico
Brazil
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of Middle East & Africa
In the competitive analysis section of the report, leading as well as prominent players of the global Uterine Polyps Drug market are broadly studied on the basis of key factors. The report offers comprehensive analysis and accurate statistics on revenue by the player for the period 2015-2020. It also offers detailed analysis supported by reliable statistics on price and revenue (global level) by player for the period 2015-2020.
The key players covered in this study
GSK
Roche
Pfizer
Novartis
Merck
Bristol-Myers
Sanofi
Teva Pharmaceutical Industries
Amgen
1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Uterine Polyps Drug Market Size Growth Rate by Type: 2020 VS 2026
1.2.2 Oral
1.2.3 Injection
1.2.4 Other
1.3 Market by Application
1.3.1 Global Uterine Polyps Drug Market Share by Application: 2020 VS 2026
1.3.2 Hospital
1.3.3 Clinic
1.3.4 Homecare
1.3.5 Other
1.4 Study Objectives
1.5 Years Considered
2 Global Growth Trends
2.1 Global Uterine Polyps Drug Market Perspective (2015-2026)
2.2 Global Uterine Polyps Drug Growth Trends by Regions
2.2.1 Uterine Polyps Drug Market Size by Regions: 2015 VS 2020 VS 2026
2.2.2 Uterine Polyps Drug Historic Market Share by Regions (2015-2020)
2.2.3 Uterine Polyps Drug Forecasted Market Size by Regions (2021-2026)
2.3 Industry Trends and Growth Strategy
2.3.1 Market Trends
2.3.2 Market Drivers
2.3.3 Market Challenges
2.3.4 Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top Uterine Polyps Drug Players by Market Size
3.1.1 Global Top Uterine Polyps Drug Players by Revenue (2015-2020)
3.1.2 Global Uterine Polyps Drug Revenue Market Share by Players (2015-2020)
3.2 Global Uterine Polyps Drug Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
3.3 Players Covered: Ranking by Uterine Polyps Drug Revenue
3.4 Global Uterine Polyps Drug Market Concentration Ratio
3.4.1 Global Uterine Polyps Drug Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Uterine Polyps Drug Revenue in 2019
3.5 Key Players Uterine Polyps Drug Area Served
3.6 Key Players Uterine Polyps Drug Product Solution and Service
3.7 Date of Enter into Uterine Polyps Drug Market
3.8 Mergers & Acquisitions, Expansion Plans
4 Uterine Polyps Drug Breakdown Data by Type (2015-2026)
4.1 Global Uterine Polyps Drug Historic Market Size by Type (2015-2020)
4.2 Global Uterine Polyps Drug Forecasted Market Size by Type (2021-2026)
5 Uterine Polyps Drug Breakdown Data by Application (2015-2026)
5.1 Global Uterine Polyps Drug Historic Market Size by Application (2015-2020)
5.2 Global Uterine Polyps Drug Forecasted Market Size by Application (2021-2026)
6 North America
6.1 North America Uterine Polyps Drug Market Size (2015-2026)
6.2 North America Uterine Polyps Drug Market Size by Type (2015-2020)
6.3 North America Uterine Polyps Drug Market Size by Application (2015-2020)
6.4 North America Uterine Polyps Drug Market Size by Country (2015-2020)
6.4.1 United States
6.4.2 Canada
7 Europe
7.1 Europe Uterine Polyps Drug Market Size (2015-2026)
7.2 Europe Uterine Polyps Drug Market Size by Type (2015-2020)
7.3 Europe Uterine Polyps Drug Market Size by Application (2015-2020)
7.4 Europe Uterine Polyps Drug Market Size by Country (2015-2020)
7.4.1 Germany
7.4.2 France
7.4.3 U.K.
7.4.4 Italy
7.4.5 Russia
7.4.6 Nordic
7.4.7 Rest of Europe
8 China
8.1 China Uterine Polyps Drug Market Size (2015-2026)
8.2 China Uterine Polyps Drug Market Size by Type (2015-2020)
8.3 China Uterine Polyps Drug Market Size by Application (2015-2020)
8.4 China Uterine Polyps Drug Market Size by Region (2015-2020)
8.4.1 China
8.4.2 Japan
8.4.3 South Korea
8.4.4 Southeast Asia
8.4.5 India
8.4.6 Australia
8.4.7 Rest of Asia-Pacific
9 Japan
9.1 Japan Uterine Polyps Drug Market Size (2015-2026)
9.2 Japan Uterine Polyps Drug Market Size by Type (2015-2020)
9.3 Japan Uterine Polyps Drug Market Size by Application (2015-2020)
9.4 Japan Uterine Polyps Drug Market Size by Country (2015-2020)
9.4.1 Mexico
9.4.2 Brazil
10 Southeast Asia
10.1 Southeast Asia Uterine Polyps Drug Market Size (2015-2026)
10.2 Southeast Asia Uterine Polyps Drug Market Size by Type (2015-2020)
10.3 Southeast Asia Uterine Polyps Drug Market Size by Application (2015-2020)
10.4 Southeast Asia Uterine Polyps Drug Market Size by Country (2015-2020)
10.4.1 Turkey
10.4.2 Saudi Arabia
10.4.3 UAE
10.4.4 Rest of Middle East & Africa
11Key Players Profiles
11.1 GSK
11.1.1 GSK Company Details
11.1.2 GSK Business Overview
11.1.3 GSK Uterine Polyps Drug Introduction
11.1.4 GSK Revenue in Uterine Polyps Drug Business (2015-2020))
11.1.5 GSK Recent Development
11.2 Roche
11.2.1 Roche Company Details
11.2.2 Roche Business Overview
11.2.3 Roche Uterine Polyps Drug Introduction
11.2.4 Roche Revenue in Uterine Polyps Drug Business (2015-2020)
11.2.5 Roche Recent Development
11.3 Pfizer
11.3.1 Pfizer Company Details
11.3.2 Pfizer Business Overview
11.3.3 Pfizer Uterine Polyps Drug Introduction
11.3.4 Pfizer Revenue in Uterine Polyps Drug Business (2015-2020)
11.3.5 Pfizer Recent Development
11.4 Novartis
11.4.1 Novartis Company Details
11.4.2 Novartis Business Overview
11.4.3 Novartis Uterine Polyps Drug Introduction
11.4.4 Novartis Revenue in Uterine Polyps Drug Business (2015-2020)
11.4.5 Novartis Recent Development
11.5 Merck
11.5.1 Merck Company Details
11.5.2 Merck Business Overview
11.5.3 Merck Uterine Polyps Drug Introduction
11.5.4 Merck Revenue in Uterine Polyps Drug Business (2015-2020)
11.5.5 Merck Recent Development
11.6 Bristol-Myers
11.6.1 Bristol-Myers Company Details
11.6.2 Bristol-Myers Business Overview
11.6.3 Bristol-Myers Uterine Polyps Drug Introduction
11.6.4 Bristol-Myers Revenue in Uterine Polyps Drug Business (2015-2020)
11.6.5 Bristol-Myers Recent Development
11.7 Sanofi
11.7.1 Sanofi Company Details
11.7.2 Sanofi Business Overview
11.7.3 Sanofi Uterine Polyps Drug Introduction
11.7.4 Sanofi Revenue in Uterine Polyps Drug Business (2015-2020)
11.7.5 Sanofi Recent Development
11.8 Teva Pharmaceutical Industries
11.8.1 Teva Pharmaceutical Industries Company Details
11.8.2 Teva Pharmaceutical Industries Business Overview
11.8.3 Teva Pharmaceutical Industries Uterine Polyps Drug Introduction
11.8.4 Teva Pharmaceutical Industries Revenue in Uterine Polyps Drug Business (2015-2020)
11.8.5 Teva Pharmaceutical Industries Recent Development
11.9 Amgen
11.9.1 Amgen Company Details
11.9.2 Amgen Business Overview
11.9.3 Amgen Uterine Polyps Drug Introduction
11.9.4 Amgen Revenue in Uterine Polyps Drug Business (2015-2020)
11.9.5 Amgen Recent Development
11.10 Mylan
11.10.1 Mylan Company Details
11.10.2 Mylan Business Overview
11.10.3 Mylan Uterine Polyps Drug Introduction
11.10.4 Mylan Revenue in Uterine Polyps Drug Business (2015-2020)
11.10.5 Mylan Recent Development
11.11 Sun Pharmaceutical Industries
10.11.1 Sun Pharmaceutical Industries Company Details
10.11.2 Sun Pharmaceutical Industries Business Overview
10.11.3 Sun Pharmaceutical Industries Uterine Polyps Drug Introduction
10.11.4 Sun Pharmaceutical Industries Revenue in Uterine Polyps Drug Business (2015-2020)
10.11.5 Sun Pharmaceutical Industries Recent Development
12Analyst’s Viewpoints/Conclusions
13Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details
Table 1. Global Uterine Polyps Drug Market Size Growth Rate by Type (US$ Million): 2020 VS 2026
Table 3. Key Players of Oral
Table 4. Key Players of Injection
Table 5. Key Players of Other
Table 6. Global Uterine Polyps Drug Market Size Growth by Application (US$ Million): 2020 VS 2026
Table 7. Global Uterine Polyps Drug Market Size by Regions (US$ Million): 2020 VS 2026
Table 8. Global Uterine Polyps Drug Market Size by Regions (2015-2020) (US$ Million)
Table 9. Global Uterine Polyps Drug Market Share by Regions (2015-2020)
Table 10. Global Uterine Polyps Drug Forecasted Market Size by Regions (2021-2026) (US$ Million)
Table 11. Global Uterine Polyps Drug Market Share by Regions (2021-2026)
Table 12. Uterine Polyps Drug Market Market Trends
Table 13. Uterine Polyps Drug Market Drivers
Table 14. Uterine Polyps Drug Market Challenges
Table 15. Uterine Polyps Drug Market Restraints
Table 16. Global Uterine Polyps Drug Revenue by Players (2015-2020) (US$ Million)
Table 17. Global Uterine Polyps Drug Market Share by Players (2015-2020)
Table 18. Global Top Uterine Polyps Drug Players by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Uterine Polyps Drug as of 2019)
Table 19. Global Uterine Polyps Drug by Players Market Concentration Ratio (CR5 and HHI)
Table 20. Key Players Headquarters and Area Served
Table 21. Key Players Uterine Polyps Drug Product Solution and Service
Table 22. Mergers & Acquisitions, Expansion Plans
Table 23. Global Uterine Polyps Drug Market Size by Type (2015-2020) (US$ Million)
Table 24. Global Uterine Polyps Drug Market Size Share by Type (2015-2020)
Table 25. Global Uterine Polyps Drug Revenue Market Share by Type (2021-2026)
Table 26. Global Uterine Polyps Drug Market Size Share by Application (2015-2020)
Table 27. Global Uterine Polyps Drug Market Size by Application (2015-2020) (US$ Million)
Table 28. Global Uterine Polyps Drug Market Size Share by Application (2021-2026)
Table 29. North America Uterine Polyps Drug Market Size by Type (2015-2020) (US$ Million)
Table 30. North America Uterine Polyps Drug Market Share by Type (2015-2020)
Table 31. North America Uterine Polyps Drug Market Size by Application (2015-2020) (US$ Million)
Table 32. North America Uterine Polyps Drug Market Share by Application (2015-2020)
Table 33. North America Uterine Polyps Drug Market Size by Country (US$ Million) (2015-2020)
Table 34. North America Uterine Polyps Drug Market Share by Country (2015-2020)
Table 35. Europe Uterine Polyps Drug Market Size by Type (2015-2020) (US$ Million)
Table 36. Europe Uterine Polyps Drug Market Share by Type (2015-2020)
Table 37. Europe Uterine Polyps Drug Market Size by Application (2015-2020) (US$ Million)
Table 38. Europe Uterine Polyps Drug Market Share by Application (2015-2020)
Table 39. Europe Uterine Polyps Drug Market Size by Country (US$ Million) (2015-2020)
Table 40. Europe Uterine Polyps Drug Market Share by Country (2015-2020)
Table 41. China Uterine Polyps Drug Market Size by Type (2015-2020) (US$ Million)
Table 42. China Uterine Polyps Drug Market Share by Type (2015-2020)
Table 43. China Uterine Polyps Drug Market Size by Application (2015-2020) (US$ Million)
Table 44. China Uterine Polyps Drug Market Share by Application (2015-2020)
Table 45. China Uterine Polyps Drug Market Size by Region (US$ Million) (2015-2020)
Table 46. China Uterine Polyps Drug Market Share by Region (2015-2020)
Table 47. Japan Uterine Polyps Drug Market Size by Type (2015-2020) (US$ Million)
Table 48. Japan Uterine Polyps Drug Market Share by Type (2015-2020)
Table 49. Japan Uterine Polyps Drug Market Size by Application (2015-2020) (US$ Million)
Table 50. Japan Uterine Polyps Drug Market Share by Application (2015-2020)
Table 51. Japan Uterine Polyps Drug Market Size by Country (US$ Million) (2015-2020)
Table 52. Japan Uterine Polyps Drug Market Share by Country (2015-2020)
Table 53. Southeast Asia Uterine Polyps Drug Market Size by Type (2015-2020) (US$ Million)
Table 54. Southeast Asia Uterine Polyps Drug Market Share by Type (2015-2020)
Table 55. Southeast Asia Uterine Polyps Drug Market Size by Application (2015-2020) (US$ Million)
Table 56. Southeast Asia Uterine Polyps Drug Market Share by Application (2015-2020)
Table 57. Southeast Asia Uterine Polyps Drug Market Size by Country (US$ Million) (2015-2020)
Table 58. Southeast Asia Uterine Polyps Drug Market Share by Country (2015-2020)
Table 59. GSK Company Details
Table 60. GSK Business Overview
Table 61. GSK Product
Table 62. GSK Revenue in Uterine Polyps Drug Business (2015-2020) (US$ Million)
Table 63. GSK Recent Development
Table 64. Roche Company Details
Table 65. Roche Business Overview
Table 66. Roche Product
Table 67. Roche Revenue in Uterine Polyps Drug Business (2015-2020) (US$ Million)
Table 68. Roche Recent Development
Table 69. Pfizer Company Details
Table 70. Pfizer Business Overview
Table 71. Pfizer Product
Table 72. Pfizer Revenue in Uterine Polyps Drug Business (2015-2020) (US$ Million)
Table 73. Pfizer Recent Development
Table 74. Novartis Company Details
Table 75. Novartis Business Overview
Table 76. Novartis Product
Table 77. Novartis Revenue in Uterine Polyps Drug Business (2015-2020) (US$ Million)
Table 78. Novartis Recent Development
Table 79. Merck Company Details
Table 80. Merck Business Overview
Table 81. Merck Product
Table 82. Merck Revenue in Uterine Polyps Drug Business (2015-2020) (US$ Million)
Table 83. Merck Recent Development
Table 84. Bristol-Myers Company Details
Table 85. Bristol-Myers Business Overview
Table 86. Bristol-Myers Product
Table 87. Bristol-Myers Revenue in Uterine Polyps Drug Business (2015-2020) (US$ Million)
Table 88. Bristol-Myers Recent Development
Table 89. Sanofi Company Details
Table 90. Sanofi Business Overview
Table 91. Sanofi Product
Table 92. Sanofi Revenue in Uterine Polyps Drug Business (2015-2020) (US$ Million)
Table 93. Sanofi Recent Development
Table 94. Teva Pharmaceutical Industries Business Overview
Table 95. Teva Pharmaceutical Industries Product
Table 96. Teva Pharmaceutical Industries Company Details
Table 97. Teva Pharmaceutical Industries Revenue in Uterine Polyps Drug Business (2015-2020) (US$ Million)
Table 98. Teva Pharmaceutical Industries Recent Development
Table 99. Amgen Company Details
Table 100. Amgen Business Overview
Table 101. Amgen Product
Table 102. Amgen Revenue in Uterine Polyps Drug Business (2015-2020) (US$ Million)
Table 103. Amgen Recent Development
Table 104. Mylan Company Details
Table 105. Mylan Business Overview
Table 106. Mylan Product
Table 107. Mylan Revenue in Uterine Polyps Drug Business (2015-2020) (US$ Million)
Table 108. Mylan Recent Development
Table 109. Sun Pharmaceutical Industries Company Details
Table 110. Sun Pharmaceutical Industries Business Overview
Table 111. Sun Pharmaceutical Industries Product
Table 112. Sun Pharmaceutical Industries Revenue in Uterine Polyps Drug Business (2015-2020) (US$ Million)
Table 113. Sun Pharmaceutical Industries Recent Development
Table 114. Research Programs/Design for This Report
Table 115. Key Data Information from Secondary Sources
Table 116. Key Data Information from Primary Sources
List of Figures
Figure 1. Global Uterine Polyps Drug Market Share by Type: 2020 VS 2026
Figure 2. Oral Features
Figure 3. Injection Features
Figure 4. Other Features
Figure 5. Global Uterine Polyps Drug Market Share by Application: 2020 VS 2026
Figure 6. Hospital Case Studies
Figure 7. Clinic Case Studies
Figure 8. Homecare Case Studies
Figure 9. Other Case Studies
Figure 10. Uterine Polyps Drug Report Years Considered
Figure 11. Global Uterine Polyps Drug Market Size (US$ Million), YoY Growth 2015-2026
Figure 12. Global Uterine Polyps Drug Market Share by Regions: 2020 VS 2026
Figure 13. Global Uterine Polyps Drug Market Share by Regions (2021-2026)
Figure 14. Global Uterine Polyps Drug Market Share by Players in 2019
Figure 15. Global Top Uterine Polyps Drug Players by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Uterine Polyps Drug as of 2019
Figure 16. The Top 10 and 5 Players Market Share by Uterine Polyps Drug Revenue in 2019
Figure 17. North America Uterine Polyps Drug Market Size YoY Growth (2015-2026) & (US$ Million)
Figure 18. United States Uterine Polyps Drug Market Size YoY Growth (2015-2026) & (US$ Million)
Figure 19. Canada Uterine Polyps Drug Market Size YoY Growth (2015-2026) & (US$ Million)
Figure 20. Europe Uterine Polyps Drug Market Size YoY Growth (2015-2026) & (US$ Million)
Figure 21. Germany Uterine Polyps Drug Market Size YoY Growth (2015-2026) & (US$ Million)
Figure 22. France Uterine Polyps Drug Market Size YoY Growth (2015-2026) & (US$ Million)
Figure 23. U.K. Uterine Polyps Drug Market Size YoY Growth (2015-2026) & (US$ Million)
Figure 24. Italy Uterine Polyps Drug Market Size YoY Growth (2015-2026) & (US$ Million)
Figure 25. Russia Uterine Polyps Drug Market Size YoY Growth (2015-2026) & (US$ Million)
Figure 26. Nordic Uterine Polyps Drug Market Size YoY Growth (2015-2026) & (US$ Million)
Figure 27. Rest of Europe Uterine Polyps Drug Market Size YoY Growth (2015-2026) & (US$ Million)
Figure 28. Asia-Pacific Uterine Polyps Drug Market Size YoY Growth (2015-2026) & (US$ Million)
Figure 29. China Uterine Polyps Drug Market Size YoY Growth (2015-2026) & (US$ Million)
Figure 30. Japan Uterine Polyps Drug Market Size YoY Growth (2015-2026) & (US$ Million)
Figure 31. South Korea Uterine Polyps Drug Market Size YoY Growth (2015-2026) & (US$ Million)
Figure 32. Southeast Asia Uterine Polyps Drug Market Size YoY Growth (2015-2026) & (US$ Million)
Figure 33. India Uterine Polyps Drug Market Size YoY Growth (2015-2026) & (US$ Million)
Figure 34. Australia Uterine Polyps Drug Market Size YoY Growth (2015-2026) & (US$ Million)
Figure 35. Rest of Asia-Pacific Uterine Polyps Drug Market Size YoY Growth (2015-2026) & (US$ Million)
Figure 36. Latin America Uterine Polyps Drug Market Size YoY Growth (2015-2026) & (US$ Million)
Figure 37. Mexico Uterine Polyps Drug Market Size YoY Growth (2015-2026) & (US$ Million)
Figure 38. Brazil Uterine Polyps Drug Market Size YoY Growth (2015-2026) & (US$ Million)
Figure 39. Middle East & Africa Uterine Polyps Drug Market Size YoY Growth (2015-2026) & (US$ Million)
Figure 40. Turkey Uterine Polyps Drug Market Size YoY Growth (2015-2026) & (US$ Million)
Figure 41. Saudi Arabia Uterine Polyps Drug Market Size YoY Growth (2015-2026) & (US$ Million)
Figure 42. UAE Uterine Polyps Drug Market Size YoY Growth (2015-2026) & (US$ Million)
Figure 43. Rest of Middle East & Africa Uterine Polyps Drug Market Size YoY Growth (2015-2026) & (US$ Million)
Figure 44. GSK Revenue Growth Rate in Uterine Polyps Drug Business (2015-2020)
Figure 45. Roche Revenue Growth Rate in Uterine Polyps Drug Business (2015-2020)
Figure 46. Pfizer Revenue Growth Rate in Uterine Polyps Drug Business (2015-2020)
Figure 47. Novartis Revenue Growth Rate in Uterine Polyps Drug Business (2015-2020)
Figure 48. Merck Revenue Growth Rate in Uterine Polyps Drug Business (2015-2020)
Figure 49. Bristol-Myers Revenue Growth Rate in Uterine Polyps Drug Business (2015-2020)
Figure 50. Sanofi Revenue Growth Rate in Uterine Polyps Drug Business (2015-2020)
Figure 51. Teva Pharmaceutical Industries Revenue Growth Rate in Uterine Polyps Drug Business (2015-2020)
Figure 52. Amgen Revenue Growth Rate in Uterine Polyps Drug Business (2015-2020)
Figure 53. Mylan Revenue Growth Rate in Uterine Polyps Drug Business (2015-2020)
Figure 54. Sun Pharmaceutical Industries Revenue Growth Rate in Uterine Polyps Drug Business (2015-2020)
Figure 55. Bottom-up and Top-down Approaches for This Report
Figure 56. Data Triangulation
Figure 57. Key Executives Interviewed
子宮筋腫治療薬の世界市場（～2026年） Uterine fibroids are the most common benign tumors in female reproductive organs and one of the most common tumors in human body. They are mainly caused by proliferation of uterine smooth muscle cells. Market Analysis and Insights: Global Uterine Fibroids Drug Market The global Uterine Fibroids Drug…- ポリープの世界市場（～2026年） Polyps are abnormal tissue growths that most often look like small, flat bumps or tiny mushroom like stalks. Most polyps are small and less than half an inch wide. Most polyps are benign, meaning they’re noncancerous. But because they are due to abnormal cell growth, they can eventually become malig…
- 子宮がん診断検査の世界市場（～2026年） Uterus a female organ also referred as the womb is located in the lower abdomen. It supports in the fetal development until birth. In North America, the U.S. is expected to be the dominant market for uterine cancer diagnostic testing due to growing incidence of uterine cancer. Market Analysis and In…
- 子宮疾患治療薬の世界市場（～2026年） Uterus is the muscle organ in female reproductive system, which plays a great role in female reproduction and fetal development. The incidence of uterine diseases is also very high, so the treatment of uterine diseases is particularly important. Market Analysis and Insights: Global Uterine Diseases …
- 子宮筋腫治療装置の世界市場（～2026年） Uterine fibroids are noncancerous growths of the uterus that often appear during childbearing years. Also called leiomyomas (lie-o-my-O-muhs) or myomas, uterine fibroids aren't associated with an increased risk of uterine cancer and almost never develop into cancer. Market Analysis and Insights: Glo…